ABSTRACT Aims This study investigated the prognostic performance of the FIB‐3 index, composed of aspartate aminotransferase, alanine aminotransferase, and platelet count, in patients with decompensated cirrhosis and overt hepatic encephalopathy receiving rifaximin therapy. Methods Between March 2017 and March 2024, 235 patients were included in this multicenter retrospective study. The discriminatory performance of the FIB‐3 index for predicting 48‐month survival was compared with that of the FIB‐4 index, aMAP score, MELD 3.0 score, and Child–Pugh classification. Results The AUROCs for the FIB‐3 index, FIB‐4 index, aMAP score, MELD 3.0 score, and Child–Pugh classification were 0.63, 0.58, 0.57, 0.71, and 0.70, respectively. Using the FIB‐3 index as the reference model, no statistically significant differences in AUROC were observed between the FIB‐3 index and the other models ( p = 0.05, 0.2, 0.1, and 0.1, respectively). In the NRI analysis, the FIB‐3 index demonstrated significantly better discriminatory performance than the FIB‐4 index ( p < 0.001) but poorer discriminatory performance than Child–Pugh classification ( p < 0.001), whereas no significant differences were observed compared with the aMAP or MELD 3.0 scores ( p = 0.2 and 0.1, respectively). In the IDI analysis, the FIB‐3 index showed significantly better discriminatory performance than the FIB‐4 index ( p = 0.02) but poorer discriminatory performance than the MELD 3.0 score and Child–Pugh classification ( p = 0.004 and p < 0.001, respectively). Conclusions The FIB‐3 index showed better prognostic discrimination than the FIB‐4 index and may serve as a simple age‐independent fibrosis‐related marker that complements established liver function‐based prognostic models.
Takeshi Hatanaka, Satoru Kakizaki, Rintaro Kobayashi, Yuki Kanayama, Satoshi Takakusagi, Takashi Kosone et al. Prognostic Value of the FIB‐3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis. // Hepatology Research. – 2026. – DOI: 10.1111/hepr.70269. – URL: https://onlinelibrary.wiley.com/doi/10.1111/hepr.70269?af=R
Takeshi Hatanaka, Satoru Kakizaki, Rintaro Kobayashi, Yuki Kanayama, Satoshi Takakusagi, Takashi Kosone, Atsushi Naganuma, Hiroki Tojima, Yuichi Yamazaki, Hitoshi Takagi, & Toshio Uraoka (2026). Prognostic Value of the FIB‐3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis. Hepatology Research. https://doi.org/10.1111/hepr.70269
Takeshi Hatanaka, et al. “Prognostic Value of the FIB‐3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis.” Hepatology Research, 2026. doi:10.1111/hepr.70269.
@article{Hatanaka2026,
title = {Prognostic Value of the FIB‐3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis},
author = {Hatanaka, Takeshi and Kakizaki, Satoru and Kobayashi, Rintaro and Kanayama, Yuki and Takakusagi, Satoshi and Kosone, Takashi and Naganuma, Atsushi and Tojima, Hiroki and Yamazaki, Yuichi and Takagi, Hitoshi and Uraoka, Toshio},
journal = {Hepatology Research},
year = {2026},
doi = {10.1111/hepr.70269},
url = {https://onlinelibrary.wiley.com/doi/10.1111/hepr.70269?af=R}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...